Revance Therapeutics, Inc. (NASDAQ:RVNC) has been assigned an average rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $37.00.

Several analysts recently issued reports on RVNC shares. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research note on Tuesday, August 22nd. Piper Jaffray Companies set a $28.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. BidaskClub raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price objective on shares of Revance Therapeutics in a research note on Wednesday, September 6th.

In related news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total transaction of $179,208.00. Following the completion of the sale, the chief executive officer now owns 148,450 shares of the company’s stock, valued at approximately $3,500,451. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Lauren P. Silvernail sold 11,164 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $26.67, for a total transaction of $297,743.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 49,226 shares of company stock valued at $1,196,318. 18.86% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its holdings in Revance Therapeutics by 8.1% in the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 438 shares during the last quarter. Bank of America Corp DE boosted its holdings in Revance Therapeutics by 29.5% in the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 1,651 shares during the last quarter. Trexquant Investment LP acquired a new position in Revance Therapeutics in the 2nd quarter valued at about $231,000. Voya Investment Management LLC acquired a new position in Revance Therapeutics in the 2nd quarter valued at about $274,000. Finally, American International Group Inc. boosted its holdings in Revance Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 834 shares during the last quarter. Institutional investors own 89.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Revance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of “Buy” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/28/revance-therapeutics-inc-rvnc-receives-consensus-recommendation-of-buy-from-analysts-2.html.

Revance Therapeutics (NASDAQ:RVNC) opened at 26.15 on Friday. The company has a 50 day moving average of $26.02 and a 200-day moving average of $23.78. Revance Therapeutics has a one year low of $12.35 and a one year high of $28.75. The company’s market cap is $805.92 million.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.03. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. During the same quarter in the prior year, the company earned ($0.88) EPS. Revance Therapeutics’s revenue was up .0% compared to the same quarter last year. On average, equities analysts expect that Revance Therapeutics will post ($3.61) earnings per share for the current fiscal year.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.